# 1 Low booster uptake in cancer patients despite health benefits

3	Jane C. Figueiredo, <sup>1,2</sup> Julia Levy, <sup>1</sup> So Yung Choi, <sup>2</sup> Alexander M. Xu <sup>3</sup> , Noah M. Merin, <sup>4</sup> Omid						
4	Hamid, <sup>1,5</sup> Tucker Lemos, <sup>4</sup> Nathalie Nguyen, <sup>1</sup> Maimoona Nadri, <sup>1</sup> Alma Gonzalez, <sup>1</sup> Simeon						
5	Mahov, <sup>4</sup> Justin M. Darrah, <sup>4</sup> Jun Gong, <sup>1</sup> Ronald L. Paquette, <sup>4</sup> Alain C. Mita, <sup>1</sup> Robert A. Vescio, <sup>4</sup>						
6	Sarah J. Salvy, <sup>6</sup> Inderjit Mehmi, <sup>5</sup> Andrew E. Hendifar, <sup>1</sup> Ronald Natale, <sup>1</sup> Warren G.						
7	Tourtellotte, <sup>7,8</sup> V. Krishnan Ramanujan, <sup>8</sup> Carissa A. Huynh, <sup>8</sup> Kimia Sobhani, <sup>8</sup> Karen L.						
8	Reckamp, <sup>1</sup> and Akil A. Merchant <sup>4</sup>						
9							
10	<sup>1</sup> Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai						
11	Medical Center, Los Angeles, CA 90048;						
12	<sup>2</sup> Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA						
13	90048;						
14	<sup>3</sup> Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048						
15	<sup>4</sup> Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin						
16	Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048;						
17	<sup>5</sup> The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA 90025,						
18	<sup>6</sup> Research Center for Health Equity, Department of Biomedical Sciences, Los Angeles, CA						
19	90048;						
20	<sup>7</sup> Department of Neurology, Neurological Surgery and Biomedical Sciences, Cedars-Sinai						
21	Medical Center, Los Angeles, CA 90048;						
22	<sup>8</sup> Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles,						
23	CA 90048;						

## 24

### 25 Corresponding authors:

- 26 Jane C. Figueiredo, Ph.D., Department of Medicine, Division of Medical Oncology, Cedars-
- 27 Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, Email:
- 28 Jane.Figueiredo@cshs.org, Phone: 310-423-2746
- 29 Akil Merchant, M.D., Division of Hematology and Cellular Therapy, Samuel Oschin
- 30 Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles,
- 31 CA 90048, Email: <u>Akil.Merchant@cshs.org</u>, Phone: 310-423-2746

## 33 Highlights

34	COVID-19 booster vaccinations increase antibody levels and maintain T-cell responses							
35	against SARS-CoV-2 in patients receiving various anti-cancer therapies							
36	Booster vaccinations reduced all-cause mortality in patients							
37	• A significant proportion of patients remain unboosted and strategies are needed to							
38	encourage patients to be up-to-date with vaccinations							
39								
40	Summary							
41	Patients with cancer are at increased risk of death from COVID-19 and have reduced immune							
42	responses to SARS-CoV2 vaccines, necessitating regular boosters. We performed							
43	comprehensive chart reviews, surveys of patients attitudes, serology for SARS-CoV-2 antibodies							
44	and T-cell receptor (TCR) $\beta$ sequencing for cellular responses on a cohort of 982 cancer patients							
45	receiving active cancer therapy accrued between November-3-2020 and Mar-31-2023. We							
46	found that 92.3% of patients received the primer vaccine, $70.8\%$ received one monovalent							
47	booster, but only 30.1% received a bivalent booster. Booster uptake was lower under age 50, and							
48	among African American or Hispanic patients. Nearly all patients seroconverted after 2+ booster							
49	vaccinations (>99%) and improved cellular responses, demonstrating that repeated boosters							
50	could overcome poor response to vaccination. Receipt of booster vaccinations was associated							
51	with a lower risk of all-cause mortality (HR= $0.61$ , P= $0.024$ ). Booster uptake in high-risk cancer							
52	patients remains low and strategies to encourage booster uptake are needed.							

### 53 Introduction

54 Effective vaccines were developed, tested, and issued emergency use authorization (EUA) by the 55 U.S. Food and Drug Administration (FDA), European Medical Agency and other regulatory 56 agencies around the world in record time. Immunocompromised individuals were prioritized in 57 vaccine rollout strategies;[1] however, none of the Phase III clinical trials included patients with 58 cancer, fueling concerns about potential side effects and the robustness of their post-vaccine 59 immune responses.[2] Data quickly emerged to reassure patients that available vaccines were 60 safe and effective, [3] and subsequent studies reported that over 90% of patients with cancer have 61 received at least one COVID-19 vaccine.[4] However, it is unclear how many are following 62 recommendations for additional doses or "boosters." 63 64 Booster vaccinations have been reported to counteract waning immune responses to vaccination 65 and natural infection in healthy populations.[5] Several studies of the Omicron (B.1.1.529) 66 subvariants reported heightened capacity for immune evasion,[6] and reduced vaccine 67 effectiveness for first-generation monovalent COVID-19 vaccines.[7] Other reports suggest that 68 additional doses of the monovalent mRNA vaccines, [8, 9] heterologous boosting, [10, 11] and the 69 bivalent mRNA vaccines provide additional immune protection to SARS-CoV-2 B.1.1.529 70 infection and severe COVID-19 illness.[12] 71

For patients with cancer, evidence suggests that primer vaccinations elicit lower antibody titers
compared to healthy individuals, albeit dependent on disease state, co-morbidities, and
anticancer treatment status.[13-18] Subsequent booster vaccinations have been reported to

75	restore and increase antibody titers in patients similar to healthy controls, [11, 18, 19] except for						
76	patients receiving B-cell-depleting therapies and chemotherapies.[11, 19] However, even						
77	seronegative individuals appear capable of mounting T-cell responses,[14, 20] and some data						
78	suggest that T-cell responses are more robust over time compared to antibody levels.[21]						
79							
80	Changes in vaccine availability and the evolving nature of the science and public health						
81	recommendations for additional doses have likely impacted the psychosocial wellbeing of						
82	patients. During the pandemic, there was an increase in depression and anxiety rates among						
83	patients with cancer, which was exacerbated by social distancing.[22] Disruptions in cancer care						
84	services were also reported to contribute to higher levels of anxiety, loneliness and social						
85	isolation among patients.[22, 23]						
86							
87	There are unanswered questions about changes in the mental, social, and immunologic health of						
88	patients with cancer as we enter into the endemic phase of SARS-CoV-2. In this follow-up study						
89	from the SeroNet-CORALE Cancer Cohort Study, we report on vaccine uptake patterns, and						
90	examine humoral and cellular immune responses, psychosocial health, and all-cause mortality.						
91							
92	Results						
93	Patient characteristics and attitudes on SARS-CoV-2 vaccines: We enrolled 986 patients with						
94	either solid (48.7%) or hematologic (51.3%) malignancies (median age=63.0 [IQR, 52.0-70.0]						
95	years; 48.6% women, Table 1, Figure S1). Less than 8% of patients refused vaccination, and						
96	<2.0% of survey responses reported being against vaccination at any timepoint during follow-up						
97	(Figure S2). Patients who agreed that vaccines may not be safe were less likely to be up-to-date						

98	with vaccinations at any timepoint (range: $11.8-40.0\%$ v. $4.3-6.7\%$ ). Fear of adverse events has					
99	remained a common concern, but has decreased over time (46.2% from Jan to Aug-2021 v.					
100	42.7% from Oct–2022 to Mar–2023).					
101						
102	SARS-CoV-2 vaccine booster uptake: Following FDA EUA recommendations for the 1st					
103	monovalent booster in Aug–2021, a total of 698 patients (49.7% with solid tumors and $50.3\%$					
104	with hematologic malignancies) were boosted with a monovalent booster with a median time					
105	from first dose of 238.5 days (IQR=207.2-280) days. Most patients received a homologous first					
106	booster (94.6% BNT/BNT-primed with BNT 1st monovalent booster; 93.6% m1273/m1273-					
107	primed with m1273 1st monovalent booster), but heterologous boosting became more frequent					
108	for subsequent doses (only 84.0% of patients receiving 2 <sup>nd</sup> homologous booster which dropped					
109	to $62.5\%$ for the 3 <sup>rd</sup> booster).					
110						
111	Less than 35% of patients received two monovalent booster doses (median of 196 days from the					
112	$1^{st}$ monovalent booster) and only $30.1\%$ received at least one bivalent booster (95.6% after					

113 receiving at least one monovalent, **Figure 1 Panel A**). When we examined vaccine uptake by

age groups and self-identified race and ethnicity, the lowest uptake was among patients under 50

- 115 years of age compared to those over age 70 (Figure 1 Panel B), and for individuals who self-
- 116 identified as either Black or Hispanic compared to non-Hispanic White (Figure 1 Panel C).



**Figure 1:** Dynamics of SARS-CoV-2 vaccine uptake after primer and booster vaccinations in patients with cancer. **Panel A.** Plot showing number of patients with cancer who received the primer series (dark blue), 1<sup>st</sup> booster (orange), 2<sup>nd</sup> or more boosters (light blue) and bivalent booster (red) over time. **Panel B.** Plot showing cumulative number of patients with cancer who received the primer series (dark blue), 1<sup>st</sup> booster (orange), 2<sup>nd</sup> or more boosters (light blue) and bivalent booster (red) over time. **Panel B.** Plot showing cumulative number of patients with cancer who received the primer series (dark blue), 1<sup>st</sup> booster (orange), 2<sup>nd</sup> or more boosters (light blue) and bivalent booster (red) over time by age categories (< 50, 50-59, 70+) (p-values for difference in vaccine uptake by age: <0.0001 (primer series), <0.0001 (1<sup>st</sup> booster), <0.0001 (2<sup>nd</sup>+ booster), <0.0001 (bivalent booster). **Panel C.** Plot showing cumulative number of patients with cancer who received the primer series (dark blue), 1<sup>st</sup> booster (orange), 2<sup>nd</sup> or more boosters (light blue) and bivalent booster (red) over time by self-reported race and ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic/Latino, Asian, Other) (p-value for difference in vaccine uptake by race and ethnicity: <0.0001 (primer series), <0.0001 (1<sup>st</sup> booster), <0.0001 (2<sup>nd+</sup> booster), 0.0003 (bivalent booster).

118	<i>Humoral immune responses post-vaccination:</i> For the primer series, median peak IgG(S-RBD)
119	antibody levels post-vaccination (available in 44.4% of patients) differed by demographic and
120	clinical characteristics. Peak antibody levels were highest in patients $<50$ years of age (p $<0.001$ ),
121	patients who self-identified as Hispanic ( $p=0.005$ ), patients with a prior SARS-CoV-2 infection
122	(p<0.001), and patients receiving B-cell therapies (p<0.001, Figure 2 Panel A). 10.6% of
123	patients (88.4% hematologic malignancies) did not seroconvert after priming.
124	
125	Median peak IgG(S-RBD) levels increased with booster doses from 372 (IQR=51-2,475)
126	BAU/ml to 2,150 (IQR=639–3,550) BAU/ml after one booster and to 3,550 (IQR=1,324–3,550)
127	BAU/ml after two boosters. Factors related to antibody levels after one booster dose were:
128	race/ethnicity (p=0.001), vaccine type (p=0.046), prior SARS-CoV-2 infection (p<0.001),
129	ECOG status (p= $0.022$ ) and chemotherapy use (p= $0.023$ , Figure 2 Panel B). Among those with
130	2+ boosters, nearly all reached the threshold of IgG(S-RBD) antibody levels; male patients and
131	those with a prior COVID infection had higher peak levels (Figure 2 Panel C). Rates of non-
132	seroconversion after boosting were: $3.3\%$ after one monovalent dose and $1.0\%$ after two
133	monovalent doses.



Figure 2: Box and whisker plots showing peak IgG (S-RBD) antibody levels after primer (n=404), post-monovalent booster #1 (n=389) and post-monovalent booster #2 (n=203) among patients with cancer by selected clinical and vaccine characteristics. P-values less than 0.05 are bolded.



144	Among patients who were seronegative after priming, 18.9% exhibited a T-cell response using
145	the T-detect metric. These patients were all hematologic malignancies with most receiving B-cell
146	targeted therapies. Among all patients after priming, we observed a modest correlation was
147	between IgG(S) and breadth, and IgG(S) and depth [Spearman's rho=0.602 and 0.595, p-
148	values<0.001, respectively].
149	
150	Symptoms post-vaccination: Among vaccinated patients completing a post-vaccination survey,
151	symptoms were highest for the second dose and lowest for the third dose. Symptoms included
151 152	symptoms were highest for the second dose and lowest for the third dose. Symptoms included site pain (59.5%, 48.1%, 9.1%), fatigue (39.2%, 48.1%, 4.5%), headaches or dizziness (15.2%,
151 152 153	symptoms were highest for the second dose and lowest for the third dose. Symptoms included site pain (59.5%, 48.1%, 9.1%), fatigue (39.2%, 48.1%, 4.5%), headaches or dizziness (15.2%, 16.0%, 6.8%), fever (19.0%, 37.7%, 11.4%) and muscle aches (6.3%, 11.3%, 4.5%) after dose
151 152 153 154	symptoms were highest for the second dose and lowest for the third dose. Symptoms included site pain (59·5%, 48·1%, 9·1%), fatigue (39·2%, 48·1%, 4·5%), headaches or dizziness (15·2%, 16·0%, 6·8%), fever (19·0%, 37·7%, 11·4%) and muscle aches (6·3%, 11·3%, 4·5%) after dose 1, 2 and 3, respectively ( <b>Figure S3</b> ). No serious toxicities attributable to vaccination were

- 155 observed in the cohort.
- 156

157 Patient-reported outcomes: Self-reported anxiety levels decreased from 50.7 (SD=9.4) during 158 the period from Jan-2021 to Aug-2021 to 48.1 (SD=8.5) from Oct-2022 to Mar-2023 in all 159 patient groups regardless of their infection and vaccination status (p=0.007, Figure 3). Social 160 support as measured by its three constructs – informational, instrumental and emotional – also 161 improved over time [Jan-2021 to Aug-2021: mean T-scores=53.9 (SD=11.1), 54.7 (SD=9.8), 162 54.9 (SD=8.5) and Sept-2021 to Mar-2022: mean T-scores=57.7 (SD=10.3), 57.7 (SD=8.1), 163 57.5 (SD=7.7), respectively]. Self-reported loneliness also decreased after the first booster was 164 introduced (Jan-2021 to Aug-2021: 4.0 (SD=1.4) and Sept-2021 to Mar-2022: 3.8 (SD=1.5), 165 p=0.042). However, depression levels remained constant over time.



**Figure 3:** Change in six self-reported HR-QOL measures over the course of the pandemic defined by four time periods: (1) Jan-2021 through Aug-2021 when the primer series was recommended/available; (2) Sept-2021 through Mar-2022 when the first monovalent (MV) booster was recommended/available; (3) April-2022 through Sept-2022 when the second MV booster was recommended/available; and (4) Oct-2022 through Mar-2023 when a bivalent booster was recommended/available. **Panel A** show scores for anxiety, depression and loneliness; and **Panel B** show scores for informational support, instrumental support and emotional support. Scores for anxiety, depression and support were converted to a T-score, which is used to compare sample scores versus the general population (mean=50, SD=10). Higher T-scores correspond to higher levels. For the loneliness scale, scores were summed and ranged from 3 (least) to 9 (most lonely). The arrow depicts the direction of benefit. For each of the four time periods, least-squares means and 95% confidence limits were plotted for patients separately by their infection and vaccination status at that time.

166

167 Predictors of SARS-CoV-2 infection and all-cause mortality: Overall, 40.4% of patients in this 168 patient cohort were infected either prior to (3.5%) or after (33.2%) vaccination including 169 multiple infections. Multiple infections were reported by 19.2% of patients, and 3.7% of patients 170 had infections both prior to and after vaccination. The majority of breakthrough infections was 171 after Dec-2021 when Omicron became the dominant lineage in the county. In multivariable Cox 172 model, B-cell treatment (HR=1.46, 95% CI=1.17-1.82, p=0.001), ECOG status (HR=0.69, 95% 173 CI=0.48-1.00, p=0.0497), and prior covid infection(s) (HR=3.51, 95% CI=2.85-4.34, p<0.001) 174 were significant risk factors for infection (Table S8). Hospitalization and ICU admissions for

175 COVID-19 after the emergence of Omicron were less common than before (27.9% v. 85.3% and 5.9% v. 19.2%, respectively).

177

- 178 In multivariable Cox model, all-cause mortality was associated with male sex (HR=1.72, 95%
- 179 CI=1.14-2.57, p=0.009), receipt of chemotherapy (HR=1.76, 95% CI=1.18-2.63, p=0.006),
- 180 ECOG status of 2 to 4 (HR=2·27, 95% CI=1·27-4·06, p=0·006) and not receiving a booster dose
- 181 (HR=0.61, 95% CI=0.40-0.94, p=0.024, **Table 2**). By cancer type, receiving a booster dose was

182 significantly associated with reduced mortality in adjusted models for those with hematologic

183 malignancies (HR=0.48, 95% CI=0.24–0.94, p=0.032), but not among individuals with solid

184 malignancies (HR=0.82, 95% CI=0.45-1.51, p=0.528).

185

#### 186 **Discussion**

187 In this cohort study, nearly all patients with cancer who received two or more boosters reached 188 the threshold level indicative of seroconversion. Booster vaccinations did not appear to 189 significantly reduce risk of infection and over 40% of patients in our cohort became infected 190 with SARS-CoV-2 after vaccination, the majority after the emergence of Omicron. However, the 191 likelihood of severe illness and COVID-related death were exceedingly low. There was also a 192 significantly reduced risk of all-cause mortality associated with booster vaccinations after 193 adjustment for known demographic and clinical variables. Despite this evidence of protection, 194 booster uptake was low in this cohort of patients, with 21.9% who remain unboosted with either 195 a monovalent or bivalent booster.

196

197 Booster uptake did not appear to be linked to vaccine hesitancy in this cohort. In our first report 198 early in the pandemic, we observed higher hesitancy related to vaccine safety and adverse events 199 especially among female compared to male patients. [24] Other studies examining vaccine 200 hesitancy among patients with cancer from 2020 to 2021 also reported patients were concerned 201 about vaccine safety, adverse effects, and efficacy due to the rapid development and novelty of 202 mRNA vaccines, [25, 26] with only 49% of patients reporting that they had discussed vaccination 203 with their oncologist. [26] In this updated report, we show that patients remain concerned about 204 vaccine safety, efficacy and occurrence of adverse events, but this proportion has decreased with 205 time and the availability of booster vaccinations.

206

207 The importance of additional booster doses in maintaining immune protection against SARS-208 CoV-2 has been documented in this cohort and other studies. [18, 19, 27] Although vaccination is 209 associated with robust serological response in most cancer patients following vaccination, the 210 durability of this response is reduced in cancer patients.[13] Booster vaccinations appears to 211 increase titers beyond levels initially elicited with the primer series, even among patients with 212 initially low or no antibody titers after two vaccine doses in the primer series. Serial boosters 213 may continue to strengthen and help maintain the humoral immune response in the vast majority 214 of patients with cancer under active treatment. Still some patients, including those receiving anti-215 CD20 therapy, CD19-directed chimeric antigen receptor T-cell therapy and ibrutinib,[11]<sup>[19,]</sup> 216 28] may require alternative protective measures such as recombinant antibodies or high titer 217 intravenous immunoglobulin.

218

219 In addition to the humoral cellular response, we measured the T cell response post-vaccination. 220 While TCR response as measured by breadth/depth is influenced by HLA type,[29] the overall 221 trends indicated that TCR response was correlated with humoral response, including for those 222 with hematologic malignancies. Previous studies have shown T-cell vaccination responses in 46-223 88% of patients with solid tumors and 45–75% of patients with hematological cancers.[14, 30] In 224 patients with cancer, reduced T-cell responses to vaccination have been associated with Bruton 225 tyrosine kinase inhibitors and steroid use.[30] [31] Immune checkpoint inhibitors have been 226 found to be associated with increased T-cell immunity, [32] although it remains to be seen how 227 other explicitly T-cell-involved therapies and malignancies such as bispecific T-cell engagers for 228 hematologic malignancies or T cell lymphomas interact with vaccination. Additional factors to 229 consider for T cell immunity are the effects of exhaustion or cancer-associated T-cell anergy,[33] 230 which can prevent existing clones from expanding. This phenomenon is reflected by differential 231 clonal breadth versus depth responses, for instance in hematological cancers, where patients have 232 similar clonal breadth response as solid tumor patients but poor clonal depth, indicating a lack of 233 clonal expansion. In our data, older patients, male patients, and B-cell therapy patients all exhibit 234 this same disparity, which is abrogated in all groups after boosters, except in male patients. Thus, 235 while boosters do not appear to significantly increase T-cell immunity, they may address 236 differences seen after primer series. Additional functional studies of T cells cancer patients after 237 boosters are needed to better coorelate TCR clonal studies with direct functional assays. 238 239 We also noted improvement in self-reported anxiety levels in patients in this cohort over the last

240 two years of the pandemic regardless of their vaccine status or infection history. However,

241 depression did not significantly change over time, and remained lower than the average cancer

242	population. The World Health Organization reported that the COVID-19 pandemic triggered a							
243	25% increase in the prevalence of anxiety and depression worldwide.[34] In patients with cancer,							
244	previous studies reported heightened anxiety and depression as a results of the uncertainty of the							
245	pandemic and associated delays in cancer diagnosis or treatment.[22, 23] Patients also expressed							
246	fear and worry about the implications of their immunodeficiences and the negative consequences							
247	of contracting COVID-19 infection.[23] Our data would suggest improvement in pandemic-							
248	induced anxiety, but further data is needed to confirm this observation.							
249								
250	We further evaluated changes in three types of social support among patients in this cohort:							
251	instrumental, emotional and informational. We observed significant improvement in all three							
252	types of social support after the first booster was introduced in Aug-2021, but no substantive							
253	changes since that time. We also observed lower levels of loneliness once boosters were							
254	introduced compared to early in the pandemic. Other reports highlighted loneliness as a potential							
255	concern among immunocompromised patients who were more likely to practice recommended							
256	preventive social distancing measures than adults without cancer,[35] leading to increased social							
257	isolation.[22] However, in recent years as the COVID-19 shifted from pandemic to endemic,							
258	more guidance on vaccination schedules became available in addition to treatment options for							
259	illness, and accordingly greater reassurance that has increased social interactions.							
260								

There are several limitations in this study. Observational studies are subject to potential selection biases, missing data and other unmeasured confounders. In this cohort study, we did not have complete serological or cellular immune data at all timepoints. Furthemore, patients who are seropositive would be expected to have a T cell response, but our finding of discordant results

265	could suggest a limitation of the T detect assay. Notably, the percentage of discordance between							
266	serologic response and TCR response differed by race and ethnicity, suggesting that perhaps							
267	differences in HLA could play a part in this discordance. Our sample size limitations also							
268	precluded analysis of certain subgroups of interest.							
269								
270	In summary, this study provides evidence that booster vaccination improved immune responses							
271	and reduced risk of mortality in cancer patients. Additional doses of COVID-19 vaccines are							
272	recommended for immunocompromised individuals, but a substantial proportion of patients are							
273	not receiving boosters. Avoiding pandemic-fatigue and simplifying an immunization schedule							
274	may encourage more patients to keep up-to-date with vaccinations.							
275								
276	Methods							
277	Study Design and Participants: The U.S. National Cancer Institute-funded Serological Sciences							
278	Network (SeroNet)-Coronavirus Risk Associations and Longitudinal Evaluation (CORALE)[13,							
279	24] study is a longitudinal cohort including cancer patients over age 18 with histologically							
280	confirmed solid or hematological malignancies. Patients were recruited in the clinical setting							
281	from Nov-3-2020 to Mar-31-2023. To focus on cancer patients with altered immunity, we over-							
282	sampled patients with B-cell/plasma cell malignancies (B-cell) and any cancer patient receiving							
283	immune checkpoint inhibitors (ICI). The study was approval by the institutional review board							
284	and all participants provided written informed consent.							
285								
286	Clinical Data Collection: Electronic medical records were reviewed to extract clinical data							
287	including tumor type (ICD-10 codes) and anti-cancer treatment regimens and timing of							

288	administration relative to vaccination. Active anticancer treatment status was defined as any
289	therapy within six months prior to and up to 14 days post-vaccination. For transplant recipients,
290	patients within one year of autologous stem cell transplant or within two years of allogeneic stem
291	cell transplant from vaccination were regarded as under active treatment. SARS-CoV-2
292	vaccination status, vaccine type and dates of administration were obtained from medical records
293	and linkage to the California Immunization Registry. We use the date of Dec-25-2021 to define
294	the timepoint when the Omicron SARS-CoV-2 lineage became dominant in the local catchment
295	area. Primer vaccination was defined as receiving either one, two or three doses of mRNA
296	vaccine [Pfizer-BioNtech BNT162b2 (BNT) or Moderna/NIH mRNA-1273 (m1273)] within 120
297	days, or one-dose of the Janssen Ad26.COV2.S (Ad26). Booster vaccinations were defined as
298	receipt of any type of mRNA vaccine or Ad26 after 120 days the first dose. In August and
299	September 2022, bivalent versions (original and omicron BA.4/BA.5 variant) of the vaccine
300	from Pfizer and Moderna were authorized for use as booster doses in individuals aged 18 years
301	of age or older in the U.S.
302	

*Questionnaire Data:* Self-administered questionnaires were sent electronically to patients at the
 time of enrollment, following vaccinations, 6-month after enrollment and annually thereafter.
 Surveys included questions regarding medical history, lifestyle, vaccine attitudes and quality of
 life.

307 <u>Vaccine hesitancy</u>: Perspectives and attitudes towards the vaccine were measured using a
 308 modified version of the World Health Organization (WHO) Vaccine Hesitancy Scale and Group 309 Based Medical Mistrust Scale. The resulting instrument had eight questions and participants

were asked to indicate how strongly they agreed or disagreed with a statement using a five-pointlikert scale.

312 Patient Reported Outcomes (PROs): The Patient-Reported Outcomes Measurement Information 313 System (PROMIS) short form measures were used to assess anxiety, depression, instrumental 314 support, informational support, and emotional support. Items assessing emotional support 315 inquired about whether respondents had a confidante or someone to talk about problems, or 316 someone who made them feel appreciated.[36] Instrumental support items asked whether 317 respondents had someone to help them take care of daily living tasks as needed, such as helping 318 with chores, running errands, helping out when sick, or helping with transportation for medical 319 care.[36] Items on informational support asked about whether respondents had someone who 320 could give advice, provide suggestions, or give helpful information about life decisions.[36] 321 Higher T scores indicated higher perceived depression, anxiety, emotional, instrumental, and 322 informational social support. 323 Loneliness: The UCLA 3-Item Loneliness Scale [37] was used to capture how often individuals 324 felt that they "lack companionship", were "left out", and "isolated from others." Responses to all 325 items were averaged to create a composite loneliness score with higher values indicating greater 326 loneliness.[38] This scale has been used in previous longitudinal studies and shows good internal 327 consistency, as well as concurrent and discriminant validity.[37] 328 *Side effects:* A self-administered symptoms questionnaire was given to patients after vaccine 329 administrations (dose 1, 2 and 3) to collect occurrence and severity of injection site pain, headache, fatigue, fever, pain, redness, and/or swelling at the injection site. 330

331

332 SARS-CoV-2 Immunoglobulin G Antibody Testing: Peripheral blood was collected from 333 participants approximately every 3-6 months. Serological testing for antibodies to the receptor 334 binding domain (RBD) of the S1 subunit of the viral spike protein [IgG(S-RBD)] and antibodies 335 targeting the viral nucleocapsid protein (IgG(N)) was performed using the SARS-CoV-2 IgG II 336 and SARS-CoV-2 IgG assays, respectively [Abbott Diagnostics (Illinois, U.S.)]. We present 337 findings using the WHO unit (binding antibody unit per ml [BAU/ml]) based on the 338 mathematical relationship of BAU/ml=0.142\*AU/ml.[39] The minimal threshold for 339 seroconversion was defined as IgG(S-RBD)=7.1 BAU/ml.[40] Detectable antibody responses 340 were classified as "low" (7.1–590.72 BAU/ml) and "high" (≥590.72 BAU/ml). The 590.72 341 BAU/ml threshold was shown to correspond to a 0.95 probability of obtaining a PRNT ID50 at a 342 1:250 dilution and is a representative of a high titer and correlate of neutralization.[41] Values 343 were cutoff at 25,000 AU/ml (3,550 BAU/ml).

344

T-Cell Receptoire (TCR): Sequencing of human TCRβ chains was performed on DNA extracted
from buffy coat specimens using the immunoSEQ Assay (Adaptive Biotechnologies, Seattle,
WA). After bias-controlled multiplex PCR and high-throughput sequencing, the absolute
abundance of unique TCRβ CDR3 regions and the corresponding T cell fractions by template
count normalization are quantified.[42] SARS-CoV-2 spike or other non-spike SARS-CoV-2
protein specificities for CDR3s are assigned using reference lists generated by Adaptive
Biotechnologies, which have been described previously.[29]

The primary metrics used to summarize SARS-CoV-2 TCR results are: T-detect, breadth and depth. T-detect is a binary variable analogous to seropositivity, with a threshold defined by

Adaptive Biotechnologies. Clonal breadth is defined as the number of unique annotated rearrangements divided by the total number of unique productive rearrangements in each sample (\*1000 in all figures). Clonal depth is calculated by a formula described previously, [43] which can be interpreted as the relative number of clonal expansion generations across the TCRs, as normalized by the total number of TCRs in the sample.[44]

360

361 Statistical Analysis: Time of vaccine uptake was visualized using cumulative incidence curve 362 and compared by age and self-reported race/ethnicity categories using log-rank tests. Patient 363 demographic and clinical characteristics were summarized by cancer type (solid v. hematologic) 364 using median and interquartile range (IQR) or mean and standard deviation (SD) for continuous 365 variables and frequencies and percentages for categorical variables. Kruskal-Wallis or Wilcoxon 366 Rank Sum tests were used to compare continuous variables and Chi-squared tests or Fisher's 367 exact tests for categorical variables. Peak quantitative IgG(S-RBD) levels were compared across 368 patients' characteristics using Kruskal-Wallis test at time of priming and boosting separately. 369 Similarly, TCR depth and breadth were compared across patient characteristics at vaccine 370 timepoints. The correlation between IgG levels and TCR depth and breadth were examined by 371 calculating Spearman's rank correlation coefficient.

372

For PROs, scores were converted to a T-score, which is used to compare sample scores versus the general population (mean=50, SD=10). Higher T-scores correspond to higher levels (for example, greater anxiety). For the loneliness scale, scores were summed and ranged from 3 (least) to 9 (most lonely). Mixed models and least-squares means were used to compare

377	constructs over the time course of vaccine recommendations adjusted for infection and status of
378	vaccine uptake.

- 380 Primary clinical outcomes of interest were SARS-CoV-2 infection (at any timepoint) and all-
- 381 cause mortality. Cox models with time dependent covariates were used to examine associations
- 382 of selected predictors and SARS-CoV-2 infection and all-cause mortality. We focused on the
- 383 following demographic and clinical predictors: age, sex, race and ethnicity, tumor type,
- 384 treatment, ECOG status, booster vaccination status and infection statu. For all-cause mortality,
- 385 we excluded individuals who were never vaccinated (76 individuals) and who died within 120
- 386 days from the first vaccination (9 individuals).
- 387
- 388 *P* value <.05 was considered statistically significant. Statistical analysis was performed in R,
- 389 version 4.2.2.
- 390

## 391 Acknowledgements

We sincerely appreciate all SeroNet-CORALE participants and study staff. This work was
supported by NCI SeroNet U54 CA260560, and by the Biobank and Biostatistics Shared
Resource of Cedars-Sinai Cancer. We are also grateful to all the front-line healthcare workers in
our healthcare system who continue to be dedicated to delivering the highest quality care for all
patients.

397

#### 398 Authors Contributions

- 399 J.C.F, A.M., K.R., N.M. were responsible for the conceptualization. K.R., R.V., J.D., J.G., N.N.,
- 400 A.G. W.T., M.N., J.L., N.M., O.M., R.N., I.M., A.H., A.M., R.P., R.N. were responsible for
- 401 patient recruitment. N.N., K.S., W.T., S.C. were responsible for the sample preparation. S.S. and
- 402 J.C.F. were responsible for the selection of surveys. S.C., J.C.F., E.K., K.S., T.L., S.M., O.H.
- 403 were responsible for the data analysis and data curation. J.C.F, A.M., S.C., N.M., O.H. were
- 404 responsible for interpreting findings. J.C.F., K.R., A.M. W.T., N.M., O.H. were responsible for
- 405 the overall supervision and funding acquisition. This work was supported by the Biobank and

406 Biostatistics Shared Resources of Cedars-Sinai Cancer (S.C., V.K.R., C.H., W.T., and K.S.) All

407 authors were responsible for reviewing and editing the final manuscript.

408

#### 409 **Declaration of Interests**

- 410 NM holds a consultant or advisory role at Amgen, Kite, Epizyme, TG Therapeutics, ADC
- 411 Therapeutics, and has research funding from Miltenyi, Teva, and Amgen. JG holds a consultant
- 412 or advisory role at EMD Serono; Elsevier; Exelixis; QED Therapeutics; Natera, Basilea,
- 413 HalioDx, Eisai, Janssen. OH has obtained consulting fees/support meetings/travel/Financial

414	interests in A	lkermes, Amgen	, Bactonix,	Beigene,	Bioatla,	BMS,	Esai, I	Roche,	Genentech.
			, ,	L) /		,			

- 415 Georgiamune, GigaGen, Grit Bio, GSK, Idera, Immunocore, Incyte, Instilbio, IO Bio, Iovance,
- 416 Janssen, KSQ, Merck Moderna, Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics,
- 417 Tempus, Vial, Zelluna. KR holds a consultant or advisory role at Amgen, AstraZeneca,
- 418 Blueprint, Boehringer Ingelheim, Daiichi Sankyo, EMD Soreno, Genentech, GSK, Janssen,
- 419 Lilly, Merck KGA, Mirati, Seattle Genetics, Takeda. JD holds a consultant or advisory role Kite
- 420 Pharma and Morphosys. RV is on the Speaker's Bureau for: Amgen, Bristol Myers Squib, Glaxo
- 421 Smith Klein, Janssen, Karyopharm, and Takeda Pharmaceuticals. AM holds a consultant or
- 422 advisory role at Novartis and Morphosys and has research funding from Amgen and Pfizer. All
- 423 remaining authors have no COI to report.
- 424

#### 425 Inclusion and Diversity

426 We support inclusive, diverse and equitable conduct of research.

427

#### 429 Figure Legends

451

430 Figure 1: Dynamics of SARS-CoV-2 vaccine uptake after primer and booster vaccinations in 431 patients with cancer. Panel A. Plot showing number of patients with cancer who received the primer series (dark blue), 1<sup>st</sup> booster (orange), 2<sup>nd</sup> or more boosters (light blue) and bivalent 432 433 booster (red) over time. Panel B. Plot showing cumulative number of patients with cancer who received the primer series (dark blue), 1st booster (orange), 2nd or more boosters (light blue) and 434 435 bivalent booster (red) over time by age categories (< 50, 50-59, 70+) (p-values for difference in vaccine uptake by age: <0.0001 (primer series), <0.0001 (1<sup>st</sup> booster), <0.0001 (2<sup>nd</sup>+ booster), 436 437 <0.0001 (bivalent booster). Panel C. Plot showing cumulative number of patients with cancer who received the primer series (dark blue), 1<sup>st</sup> booster (orange), 2<sup>nd</sup> or more boosters (light blue) 438 439 and bivalent booster (red) over time by self-reported race and ethnicity (non-Hispanic White, 440 non-Hispanic Black, Hispanic/Latino, Asian, Other) (p-value for difference in vaccine uptake by 441 race and ethnicity: <0.0001 (primer series), <0.0001 (1<sup>st</sup> booster), <0.0001 (2<sup>nd</sup>+ booster), 442 0.0003 (bivalent booster). 443 Figure 2: Box and whisker plots showing peak IgG (S-RBD) antibody levels after primer 444 (n=404), post-monovalent booster #1 (n=389) and post-monovalent booster #2 (n=203) among 445 patients with cancer by selected clinical and vaccine characteristics. P-values less than 0.05 are 446 bolded. Figure 3: Change in six self-reported HR-QOL measures over the course of the pandemic 447 448 defined by four time periods: (1) Jan-2021 through Aug-2021 when the primer series was 449 recommended/available; (2) Sept-2021 through Mar-2022 when the first monovalent (MV) 450 booster was recommended/available; (3) April-2022 through Sept-2022 when the second MV

24

booster was recommended/available; and (4) Oct-2022 through Mar-2023 when a bivalent

- 452 booster was recommended/available. Panel A show scores for anxiety, depression and
- 453 loneliness; and **Panel B** show scores for informational support, instrumental support and
- 454 emotional support. Scores for anxiety, depression and support were converted to a T-score,
- 455 which is used to compare sample scores versus the general population (mean=50, SD=10).
- 456 Higher T-scores correspond to higher levels. For the loneliness scale, scores were summed and
- 457 ranged from 3 (least) to 9 (most lonely). The arrow depicts the direction of benefit. For each of
- 458 the four time periods, least-squares means and 95% confidence limits were plotted for patients
- 459 separately by their infection and vaccination status at that time.

#### 461 **References**

- Ribas, A., et al., *Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.* Cancer Discov, 2021. 11(2): p. 233-236.
- 464 2. Fendler, A., et al., *COVID-19 vaccines in patients with cancer: immunogenicity, efficacy*465 *and safety.* Nat Rev Clin Oncol, 2022. 19(6): p. 385-401.
- Tran, S., T.H. Truong, and A. Narendran, *Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.* Eur J Cancer, 2021. **159**: p. 259-274.
- 468 4. Hirst, J., et al., Uptake of COVID-19 vaccination in people with blood cancer:
  469 Population-level cohort study of 12 million patients in England. Eur J Cancer, 2023. 183:
  470 p. 162-170.
- 471 5. Goldberg, Y., et al., *Waning Immunity after the BNT162b2 Vaccine in Israel*. N Engl J
  472 Med, 2021. 385(24): p. e85.
- 473 6. Planas, D., et al., *Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to*474 *neutralizing antibodies.* Nat Commun, 2023. 14(1): p. 824.
- Feikin, D.R., et al., Assessing COVID-19 vaccine effectiveness against Omicron *subvariants: Report from a meeting of the World Health Organization*. Vaccine, 2023.
  41(14): p. 2329-38.
- 8. Rottenberg, Y., et al., Assessment of Response to a Third Dose of the SARS-CoV-2
  BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment.
  JAMA Oncol, 2022. 8(2): p. 300-301.
- 481
  481
  482
  482
  482
  483
  484
  484
  484
  484
  485
  484
  485
  486
  486
  486
  487
  487
  487
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
  488
- Munro, A.P.S., et al., Safety and immunogenicity of seven COVID-19 vaccines as a third
  dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COVBOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, 2021. **398**(10318): p. 2258-2276.
- 487 11. Debie, Y., et al., Humoral and Cellular Immune Responses against SARS-CoV-2 after
  488 Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus
  489 ChAdOx1 in Patients with Cancer. Clin Cancer Res, 2023. 29(3): p. 635-646.
- Lin, D.Y., et al., *Effectiveness of Bivalent Boosters against Severe Omicron Infection*. N
  Engl J Med, 2023. 388(8): p. 764-766.
- 492 13. Figueiredo, J.C., et al., *Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral*493 *Immune Responses in Patients with Cancer*. Cancer Res, 2021. 81(24): p. 6273-6280.
- 494 14. Monin, L., et al., Safety and immunogenicity of one versus two doses of the COVID-19
  495 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective
  496 observational study. Lancet Oncol, 2021. 22(6): p. 765-778.
- 497 15. Goshen-Lago, T., et al., Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2
  498 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol, 2021. 7(10): p.
  499 1507-1513.
- Massarweh, A., et al., Evaluation of Seropositivity Following BNT162b2 Messenger RNA
   Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA
   Oncol, 2021. 7(8): p. 1133-1140.
- 50317.Naranbhai, V., et al., Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in504Patients With Cancer: The CANVAX Cohort Study. J Clin Oncol, 2022. 40(1): p. 12-23.

<ul> <li>With Lung Cancer After Primary Immunization and Booster: Reactivity to the CoV-2 WT Virus and Omicron Variant. J Clin Oncol, 2022. 40(33): p. 3808-3</li> <li>Haggenburg, S., et al., Antibody Response in Immunocompromised Patients W Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Scherers</li> </ul>	? <i>SARS-</i> 816.
<ul> <li>507 CoV-2 WT Virus and Omicron Variant. J Clin Oncol, 2022. 40(33): p. 3808-3</li> <li>508 19. Haggenburg, S., et al., Antibody Response in Immunocompromised Patients N Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Scherer</li> </ul>	816.
508 19. Haggenburg, S., et al., Antibody Response in Immunocompromised Patients W 509 Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Sche	010.
509 Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Scho	Vith
$-307$ Itematorized Cancers may received a $J$ -Dose $m_{11}/n^{-1}/J$ value $m_{11}/m^{-1}/J$	dule for
510 <i>COVID-19.</i> JAMA Oncol, 2022. <b>8</b> (10): p. 1477-1483.	<i>j</i> -
511 20. Oosting, S.F., et al., mRNA-1273 COVID-19 vaccination in patients receiving	r
512 chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a	ı
513 prospective, multicentre, non-inferiority trial, Lancet Oncol. 2021. 22(12): p.	1681-1691.
514 21. McKenzie, D.R., et al., Boosting of Waned Humoral and Cellular Responses	to SARS-
515 <i>CoV-2 Variants of Concern Among Patients with Cancer</i> . Cancer Res Commu	un, 2022.
516 <b>2</b> (11): p. 1449-1461.	,
517 22. Leach, C.R., et al., <i>Cancer survivor worries about treatment disruption and d</i>	etrimental
518 <i>health outcomes due to the COVID-19 pandemic</i> . J Psychosoc Oncol, 2021. <b>3</b>	<b>9</b> (3): p.
519 347-365.	
520 23. Kosir, U., et al., The impact of COVID-19 on the cancer care of adolescents a	and young
521 adults and their well-being: Results from an online survey conducted in the ed	arly stages
522 of the pandemic. Cancer, 2020. <b>126</b> (19): p. 4414-4422.	. 6
523 24. Figueiredo, J.C., et al., SARS-CoV-2 vaccine uptake, perspectives, and advers	e reactions
524 following vaccination in patients with cancer undergoing treatment. Ann Onc	col, 2022.
525 <b>33</b> (1): p. 109-111.	,
526 25. Marijanovic, I., et al., Acceptance of COVID-19 Vaccination and Its Associate	ed Factors
527 Among Cancer Patients Attending the Oncology Clinic of University Clinical	Hospital
528 Mostar, Bosnia and Herzegovina: A Cross-Sectional Study. Med Sci Monit, 2	2021. <b>27</b> : p.
529 e932788.	1
530 26. Souan, L., et al., An update on the impact of SARS-CoV-2 pandemic public aw	vareness on
531 <i>cancer patients' COVID-19 vaccine compliance: Outcomes and recommendat</i>	tions. Front
532 Public Health, 2022. <b>10</b> : p. 923815.	
533 27. Gounant, V., et al., Efficacy of Severe Acute Respiratory Syndrome Coronavir	rus-2
534 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a	Third Dose
535 in Patients With Minimal Serologic Response After Two Vaccine Doses. J The	orac Oncol,
536 2022. <b>17</b> (2): p. 239-251.	
537 28. Mairhofer, M., et al., Humoral and cellular immune responses in SARS-CoV-2	2 mRNA-
538 vaccinated patients with cancer. Cancer Cell, 2021. <b>39</b> (9): p. 1171-1172.	
539 29. Dalai, S.C., et al., Clinical Validation of a Novel T-Cell Receptor Sequencing	Assay for
540 Identification of Recent or Prior Severe Acute Respiratory Syndrome Corona	virus 2
541 <i>Infection.</i> Clin Infect Dis, 2022. <b>75</b> (12): p. 2079-2087.	
542 30. Ehmsen, S., et al., Antibody and T cell immune responses following mRNA CO	<i>OVID-19</i>
543 <i>vaccination in patients with cancer</i> . Cancer Cell, 2021. <b>39</b> (8): p. 1034-1036.	
544 31. Fiorcari, S., et al., Effects of the BTN162b2 mRNA COVID-19 vaccine in hum	oral and
545 collular immunity in nationts with abronic humphonytic lowbarnia Hamstel On	icol, 2023.
-3-3 central immunity in patients with chronic tymphocytic teakemia. Hematol Off	
546 <b>41</b> (1): p. 120-127.	
<ul> <li>546</li> <li>547</li> <li>547</li> <li>32. Yatim, N., et al., <i>Immune checkpoint inhibitors increase T cell immunity durin</i></li> </ul>	ng SARS-
<ul> <li>546</li> <li>547</li> <li>548</li> <li>548</li> <li>549</li> <li>549</li> <li>540</li> <li>541(1): p. 120-127.</li> <li>541</li> <li>541</li> <li>541</li> <li>542</li> <li>544</li> <li>544<td>ng SARS-</td></li></ul>	ng SARS-
<ul> <li>546 41(1): p. 120-127.</li> <li>547 32. Yatim, N., et al., <i>Immune checkpoint inhibitors increase T cell immunity durin</i></li> <li>548 <i>CoV-2 infection</i>. Sci Adv, 2021. 7(34).</li> <li>549 33. Schietinger, A. and P.D. Greenberg, <i>Tolerance and exhaustion: defining mech</i></li> </ul>	ng SARS- 'hanisms of T

551	34.	Organization, W.H. COVID-19 pandemic triggers 25% increase in prevalence of anxiety
552		and depression worldwide. 2022 [cited 2023 25 Aug]; Available from:
553		https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-
554		prevalence-of-anxiety-and-depression-worldwide.
555	35.	Islam, J.Y., M. Camacho-Rivera, and D.C. Vidot, Examining COVID-19 Preventive
556		Behaviors among Cancer Survivors in the United States: An Analysis of the COVID-19
557		Impact Survey. Cancer Epidemiol Biomarkers Prev, 2020. 29(12): p. 2583-2590.
558	36.	Hahn, E.A., et al., Measuring social health in the patient-reported outcomes
559		measurement information system (PROMIS): item bank development and testing. Qual
560		Life Res, 2010. <b>19</b> (7): p. 1035-44.
561	37.	Hughes, M.E., et al., A Short Scale for Measuring Loneliness in Large Surveys: Results
562		From Two Population-Based Studies. Res Aging, 2004. 26(6): p. 655-672.
563	38.	Luo, Y., et al., Loneliness, health, and mortality in old age: a national longitudinal study.
564		Soc Sci Med, 2012. <b>74</b> (6): p. 907-14.
565	39.	Kristiansen, P.A., et al., WHO International Standard for anti-SARS-CoV-2
566		<i>immunoglobulin</i> . Lancet, 2021. <b>397</b> (10282): p. 1347-1348.
567	40.	Chew, K.L., et al., Clinical evaluation of serological IgG antibody response on the
568		Abbott Architect for established SARS-CoV-2 infection. Clin Microbiol Infect, 2020.
569		<b>26</b> (9): p. 1256 e9-1256 e11.
570	41.	SARS-CoV-2 IgG II Quant Assay User Manual (Abbott Laboratories, Diagnostics
571		Division, 2000).
572	42.	Carlson, C.S., et al., Using synthetic templates to design an unbiased multiplex PCR
573		assay. Nat Commun, 2013. 4: p. 2680.
574	43.	Snyder, T.M., et al., Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2
575		Infection at Both Individual and Population Levels. medRxiv, 2020.
576	44.	Li, D., et al., The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel
577		Disease is Augmented with Anti-TNF Therapy. Inflamm Bowel Dis, 2022. 28(7): p. 1130-
578		1133.
579		

## Table 1: Characteristics of the study cohort

	Pri	mer	1 <sup>st</sup> booster (	monovalent)	>=2 <sup>nd</sup> booster (monovalent)		Bivalent booster	
	Solid	Hematologic	Solid	Hematologic	Solid	Hematologic	Solid	Hematologic
	(n=444)	(n=466)	(n=347)	(n=351)	(n=156)	(n=181)	(n=152)	(n=145)
Vaccinated proportion (%)	92.5%	92.1%	78.2%	75.3%	45.0%	51.6%	31.7%	28.7%
Age at enrollment, median (IQR) years	64.0 (55.0, 72.0)	62.0 (51.0, 69.0)	65 (56.0, 73.0)	63.0 (53.0, 70.0)	66.0 (59.8, 74.0)	66.0 (56.0, 71.0)	66.5 (60.0, 74.0)	63.0 (54.0, 71.0)
Age at diagnosis, n	416	445	322	333	145	174	137	139
Age at diagnosis, median (IQR) years	62.0 (52.0, 70.0)	57.0 (47.0, 66.0)	62.0 (52.0, 70.0)	58.0 (50.0, 66.0)	64.0 (55.0, 72.0)	60.0 (52.0, 68.8)	64.0 (55.0, 72.0)	59.0 (51.0, 69.0)
Female sex (n, %)	243 (54.7%)	197 (42.3%)	196 (56.5%)	148 (42.2%)	92 (59.0%)	70 (38.7%)	93 (61.2%)	65 (44.8%)
Race and ethnicity (n, %)								
Non-Hispanic White	273 (62.0%)	235 (50.5%)	213 (61.9%)	193 (55.1%)	104 (67.1%)	111 (61.3%)	93 (61.6%)	90 (62.1%)
Hispanic	61 (13.9%)	126 (27.1%)	47 (13.7%)	75 (21.4%)	15 (9.7%)	24 (13.3%)	17 (11.3%)	22 (15.2%)
Non-Hispanic Black	29 (6.6%)	54 (11.6%)	22 (6.4%)	42 (12.0%)	7 (4.5%)	26 (14.4%)	14 (9.3%)	16 (11.0%)
Asian	44 (10.0%)	34 (7.3%)	37 (10.8%)	28 (8.0%)	19 (12.3%)	16 (8.8%)	14 (9.3%)	15 (10.3%)
Other	33 (7.5%)	16 (3.4%)	25 (7.3%)	12 (3.4%)	10 (6.5%)	4 (2.2%)	13 (8.6%)	2 (1.4%)
Anti-cancer treatment <sup>*</sup> (n, %)								
Chemotherapy	110 (24.8%)	119 (25.5%)	104 (30.0%)	106 (30.2%)	57 (36.5%)	44 (24.3%)	59 (38.8%)	48 (33.1%)
B-cell therapy	2 (0.5%)	148 (31.8%)	2 (0.6%)	132 (37.6%)	1 (0.6%)	67 (37.0%)	1 (0.7%)	64 (44.1%)
Immune checkpoint inhibitors	118 (26.6%)	7 (1.5%)	88 (25.4%)	5 (1.4%)	37 (23.7%)	3 (1.7%)	35 (23.0%)	0 (0.0%)
Targeted therapy	53 (11.9%)	115 (24.7%)	59 (17.0%)	103 (29.3%)	34 (21.8%)	58 (32.0%)	30 (19.7%)	60 (41.4%)
Hormonal therapy	35 (7.9%)	10 (2.1%)	31 (8.9%)	5 (1.4%)	19 (12.2%)	1 (0.6%)	17 (11.2%)	2 (1.4%)
Stem cell transplant (allogeneic)	0 (0.0%)	43 (9.2%)	0 (0.0%)	36 (10.3%)	0 (0.0%)	22 (12.2%)	0 (0.0%)	17 (11.7%)
Stem cell transplant (autologous)	0 (0.0%)	28 (6.0%)	0 (0.0%)	25 (7.1%)	0 (0.0%)	17 (9.4%)	0 (0.0%)	8 (5.5%)
ECOG Status (n, %)								
0-1	241 (93.8%)	289 (94.4%)	243 (95.3%)	267 (94.3%)	130 (94.9%)	163 (97.0%)	129 (94.2%)	129 (91.5%)
2-4	16 (6.2%)	17 (5.6%)	12 (4.7%)	16 (5.7%)	7 (5.1%)	5 (3.0%)	8 (5.8%)	12 (8.5%)
Vaccine Type (n, %)								
Ad26.COV2.S	19 (4.3%)	18 (3.9%)	4 (1.2%)	3 (0.9%)	0 (0.0%)	1 (0.6%)	84 (55.3%)	84 (57.9%)
BNT162b2	224 (50.5%)	268 (57.5%)	166 (47.8%)	206 (58.7%)	68 (43.6%)	99 (55.0%)	68 (44.7%)	61 (42.1%)
mRNA-1273	201 (45.3%)	180 (38.6%)	177 (51.0%)	142 (40.5%)	88 (56.4%)	80 (44.4%)	40 (26.3%)	42 (29.0%)
Heterologous boosting (n, %)			29 (8.4%)	26 (7.4%)	26 (16.7%)	28 (15.6%)	39 (25.7%)	65 (44.8%)
SARS-CoV-2 infection prior to vaccination (n,								
%)	19 (4.3%)	32 (6.9%)	32 (9.2%)	51 (14.5%)	18 (11.5%)	38 (21.0%)	0 (0.0%)	1 (1.2%)
Serology available (n, %)	161 (36.3%)	243 (52.1%)	174 (50.1%)	215 (61.3%)	83 (53.2%)	120 (66.3%)	69 (45.4%)	84 (57.9%)
No seroconversion after vaccination	5 (3.1%)	38 (15.6%)	1 (0.6%)	12 (5.6%)	1 (1.2%)	1 (0.8%)	0 (0.0%)	1 (1.2%)

\*Up to 3 months prior to the time point of vaccination indicated in the column

Table	2: Multivariable model for	r all-cause mortalit	y among patients with	n cancer in this co	ohort

Deve di ata un	Hazard Ratio					
Fredictors	Estimate	CI	р			
Age at enrollment (ref: <50 years)						
50-69 years old	1.46	0.79 - 2.68	0.225			
70+ years old	1.19	0.61 - 2.31	0.610			
Male (ref: female)	1.72	1.14 - 2.57	0.009			
Race/Ethnicity (ref: Non-Hispanic White)						
Hispanic	0.88	0.51 - 1.53	0.653			
Non-Hispanic Black	0.97	0.47 - 1.99	0.933			
Asian	1.57	0.85 - 2.90	0.151			
Mixed/Other	1.06	0.45 - 2.47	0.897			
Patient Type (ref: Non-metastatic Solid Tumor)						
Hematologic Malignancy	0.93	0.41 - 2.11	0.865			
Metastatic Solid Tumor	1.94	0.97 - 3.87	0.059			
Chemotherapy (ref: none)	1.76	1.18 - 2.63	0.006			
B-cell Treatment (ref: none)	0.95	0.50 - 1.81	0.882			
Immune checkpoint inhibitors (ref: none)	1.07	0.63 - 1.81	0.807			
Targeted Therapy (ref: none)	1.37	0.89 - 2.11	0.156			
Hormonal Therapy (ref: none)	0.79	0.32 - 1.98	0.619			
Stem Cell Transplant (ref: none)	0.82	0.38 - 1.78	0.618			
ECOG (ref: 0 or 1)						
2-4	2.27	1.27 - 4.06	0.006			
At least one booster vaccination (ref: none)	0.61	0.40 - 0.94	0.024			
Any Covid Infection (ref: none)	1.53	1.00 - 2.35	0.052			

## **Supplementary Appendix**

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Figueiredo et al.

## **Supplementary Appendix**

## Contents

Figure S1: Consort diagram of study participants and their vaccine status	3
Figure S2: Vaccine perspectives among patients with cancer	5
Figure S3: Acute side-effects after vaccination among cancer patients	6
Figure S4: Post-vaccination T-cell repertoire responses among cancer patients	7
Table S1: Multivariable analyses of SARS-CoV-2 infection among patients with cancer	8

#### Figure S1: Consort diagram of study participants and their vaccine status









#### Figure S3: Acute side-effects after vaccination among cancer patients







## Table S1: Multivariable analyses of risk of SARS-CoV-2 infection among patients with cancer

	Hazard Ratio (Infection)					
Predictors	Estimate	95% CI	p-value			
Age at enrollment (ref: <50 years)						
50-69 years old	0.95	0.76–1.21	0.697			
70+ years old	1.04	0.79–1.38	0.783			
Male (ref: female)	0.89	0.75–1.07	0.225			
Race/Ethnicity (ref: Non-Hispanic White)						
Hispanic	1.22	0.98–1.52	0.072			
Non-Hispanic Black	0.88	0.62-1.23	0.438			
Asian	0.77	0.51-1.16	0.214			
Mixed/Other	1.01	0.67–1.53	0.952			
Patient Type (ref: Non-metastatic Solid Tumor)						
Hematologic Malignancy	1.29	0.91-1.83	0.153			
Metastatic Solid Tumor	1.16	0.81-1.65	0.426			
Chemotherapy (ref: none)	1.14	0.96–1.34	0.135			
B-cell Treatment (ref: none)	1.46	1.17-1.82	0.001			
Immune checkpoint inhibitors (ref: none)	0.85	0.60-1.20	0.358			
Targeted Therapy (ref: none)	1.18	0.98-1.43	0.086			
Hormonal Therapy (ref: none)	0.78	0.47–1.32	0.357			
Stem Cell Transplant (ref: none)	1.26	0.99–1.60	0.060			
ECOG (ref: 0 or 1)						
2-4	0.69	0.48-1.00	0.0497			
Vaccine Uptake (ref: None)						
At least 1 dose	0.92	0.51–1.66	0.793			
At least 1 mono-valent booster	0.84	0.45–1.54	0.567			
At least 1 bi-valent booster	0.63	0.31–1.27	0.195			
Any Prior Covid Infection (ref: none)	3.51	2.85-4.34	<0.001			